Motorika

Company Overview

Snapshot

Founded in January 2004, Motorika is a medical device company with 11–50 employees. The company specializes in robotic rehabilitation solutions and has filed over 30 patents to date. In January 2019, Motorika unveiled its Optimal-G Pro robotic gait rehabilitation system.

Business overview

Motorika develops robotic rehabilitation solutions for patients with neurological and orthopedic conditions, including stroke, traumatic brain injury, and spinal cord injury. Its core technology leverages neuroplasticity, repetitive motion, and biofeedback through platforms like ReoGo for upper limb therapy and Optimal-G Pro for gait rehabilitation. The company serves hospitals and clinics globally, with products commercially available in 33 countries across Europe, the U.S., and China, operating within the Health Tech & Life Sciences sector, specifically in Medical Devices and Medical Treatment & Therapeutics.

Strategic signal

In January 2019, Motorika unveiled its Optimal-G Pro robotic gait rehabilitation system, a significant product launch that expanded its portfolio of assistive devices. This introduction signaled the company's continued innovation in personalized robotic platforms for rehabilitation, aiming to improve patient outcomes by enhancing neural pathway retraining and functional recovery.

Company Intelligence Q&A

What is Motorika's primary focus?

Motorika focuses on developing robotic rehabilitation solutions for patients experiencing neurological and orthopedic conditions, such as stroke and spinal cord injury.

When was Motorika founded?

Motorika was founded in January 2004.

What significant product did Motorika unveil in January 2019?

In January 2019, Motorika unveiled its Optimal-G Pro robotic gait rehabilitation system.

What is the purpose of Motorika's ReoGo platform?

Motorika's ReoGo platform is designed for upper limb therapy, assisting in the rehabilitation of patients.

In which countries are Motorika's products commercially available?

Motorika's products are commercially available in 33 countries worldwide, including in Europe, the U.S., and China.